10.06.2016 09:00:54

DSM announces amendment to share repurchase program and reports repurchase of shares (3 June 2016 - 9 June 2016)

Royal DSM, a global science-based company active in health, nutrition and materials, today announces

that it intends to increase the running share repurchase program as announced on 22 February  2016 by an additional 300,000 ordinary shares to a total of 3,500,000 ordinary shares. The additional shares repurchased will be used to cover the interim stock dividend 2016. Based on the closing price of the DSM share on Euronext Amsterdam on 9 June 2016, this additional repurchase would be equivalent to approximately €17million. Consequently, the total consideration of the repurchase program is now estimated to be approximately €180million.

The repurchase of the additional shares will take place under the same conditions as the original program as announced on 22 February 2016.The program is anticipated to continue into Q3 2016. The total number of shares to be repurchased under the program represents approximately 1.93% of ordinary shares issued.

In accordance with the program, DSM reports that it has repurchased 139,054 of its own shares in the period from 3 June 2016 up to and including 9 June 2016 at an average price of €56.45. The consideration of this repurchase was €7.9 million.

The total number of shares repurchased under this program to date is 2,725,001 shares for a total consideration €135.8 million.

 

DSM - Bright Science. Brighter Living.(TM)

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.


For more information:

DSM Corporate Communications
Stephen Hufton
tel. +31 (0) 45 5787029
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31 (0) 45 5782864
e-mail investor.relations@dsm.com

 




This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM N.V. via Globenewswire

HUG#2019442

Nachrichten zu DSM NVmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu DSM NVmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

DSM NV 108,95 -0,86% DSM NV